Skip to content
OpenCapital
Get started

AptarGroup ATR Pharma — Adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet

Discontinued — last reported Q2 '22

Similar metrics at other companies

International Flavors & Fragrances logo
IFFPharma Solutions — Adjusted Operating EBITDA
$22M-62.1%
Baxter International logo
BAXPharmaceuticals — Segment operating income
$46M-27.0%
BrightSpring Health Services, Inc. logo
BTSGPharmacy Solutions — Earnings Before Interest Income Taxes Depreciation And Amortization From Reportable
$169.07M+46.1%
CVS Health logo
CVSPharmacy & Consumer Wellness — Adjusted operating income (loss)
$1.2B-8.8%
Tenet Healthcare logo
THCOperating Segments — Adjusted Earnings Before Interest Tax Depreciation And Amortization
$665M+26.2%
International Flavors & Fragrances logo
IFFHealth & Biosciences — Segment Adjusted Operating EBITDA
$153M+10.9%

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S2×-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept atr:Adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet.

The official record: AptarGroup’s 10-Q, filed July 29, 2022, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet?
AptarGroup (ATR) reported pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet of $111.01M in Q2 2022.
What does pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet mean?
The core operating profit of the Pharma segment, excluding non-cash expenses and one-time adjustments.
How do you interpret pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet?
An increase indicates improved operational efficiency and stronger profit margins within the Pharma business unit.
How does pharma — adjustedincomelossfromcontinuingoperationsbeforeinterestexpenseinterestincomeincometaxesdepreciationamortizationextraordinaryitemsnoncontrollinginterestsnet compare across companies?
Commonly referred to as Segment Adjusted EBITDA, this is a standard measure for evaluating business unit performance across manufacturing and life sciences peers.